| Patient | Phillis Wheatley |
|---|---|
| Date of birth | 2006-07-01 |
| Identifiers | MRN HR-EN015-SYN; SSN (made up) 000-15-3360 |
| Document date | 2026-02-23 |
| Author | Abena Hartley-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Diagnosis visit: lung function and FeNO results with the pulmonology consultation. [S]
Miss Wheatley returns two weeks after her first visit. This morning she had spirometry before and after albuterol and FeNO in the pulmonary function laboratory, and she then saw Dr. Fairbanks-Mensah. Her symptoms are unchanged in the cold weather: wheeze and cough on three or four days a week, waking with a tight chest about twice a month, and breathlessness climbing hills in the wind. The tuberculosis blood test and urine pregnancy test from the first visit were negative. She wants to understand exactly what the tests show and asks whether she will be well enough to travel by sea later in the spring. She came alone and was seen alone. [S]
| Element | Detail |
|---|---|
| Tests this morning | Spirometry with bronchodilator response, and FeNO |
| Results from the first visit | Interferon-gamma release assay negative; urine pregnancy test negative; chest X-ray clear; blood eosinophils 0.38 |
| Her question | Is it asthma, and can she travel by sea in the spring? |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Wheeze and cough three or four days a week; night waking about twice a month; breathless on hills in cold air |
| Constitutional | Negative | No fever, night sweats or weight loss; weight 45.8 kg |
| Ears, nose, mouth, and throat | Negative | No nasal blockage or hoarseness |
| Psychiatric | Negative | Calm; keen to understand her results |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Budesonide-formoterol 160/4.5 mcg inhaler as needed only (GINA track 1, step 2, anti-inflammatory reliever): one inhalation whenever needed for symptoms or before exercise in the cold, no more than 12 inhalations a day | One inhalation as needed | Respiratory tract route | 2026-02-23 to 2026-09-21 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-23 | Body height | 152 | cm | S |
| 2026-02-23 | Body weight | 45.8 | kg | S |
| 2026-02-23 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-02-23 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-02-23 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-02-23 | Heart rate | 82 | /min | S |
| 2026-02-23 | Respiratory rate | 16 | /min | S |
| 2026-02-23 | Body temperature | 36.6 | Cel | S |
| 2026-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-23 | FEV1 --pre bronchodilation | 2.24 | L | Lower limit of normal; predicted 2.70 L; lower limit of normal 2.17 L (GLI Global race-neutral equations) | Normal | S |
| 2026-02-23 | FEV1 --post bronchodilation | 2.57 | L | Lower limit of normal; predicted 2.70 L; lower limit of normal 2.17 L (GLI Global race-neutral equations) | Normal | S |
| 2026-02-23 | FEV1 measured/predicted | 83 | % | GLI Global race-neutral equations | Normal | S |
| 2026-02-23 | FEV1/FVC | 0.72 | {ratio} | Lower limit of normal for her age (GLI Global) | Low | S |
| 2026-02-23 | FEV1/FVC --post bronchodilation | 0.8 | {ratio} | Lower limit of normal for her age (GLI Global) | Normal | S |
| 2026-02-23 | Fractional concentration of exhaled nitric oxide | 38 | [ppb] | Above 50 ppb high; 25 to 50 intermediate (ATS) | High | S |
| 2026-02-23 | IgE [Units/volume] in Serum or Plasma | 165 | [IU]/mL | <=100 [IU]/mL | High | S |
| 2026-02-23 | Total score [ACT] | 16 | {score} | S |
Vital signs recorded on 2026-02-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Slight, composed and attentive; speaks in full sentences; weight 45.8 kg; oxygen saturation 98 percent |
| Respiratory | Faint expiratory wheeze on forced expiration; no crackles |
| Cardiovascular | Regular rhythm; no murmur |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Wheeze, cough and breathlessness this winter, for about three months: symptoms on three or four days a week, waking with cough and a tight chest about twice a month, breathless climbing the hill streets in cold air; worse with cold wind, kitchen and fireplace smoke, and colds; called a weak chest and asthma since childhood but never tested or treated. Asthma to be confirmed with spirometry before and after bronchodilator and FeNO | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to her documented frail, asthmatic childhood. Superseded by the diagnosis at the second visit. |
| Asthma, confirmed, mild persistent: variable airflow obstruction (FEV1/FVC 0.72, below the lower limit of normal, rising to 0.80 after bronchodilator; FEV1 2.24 L, 83 percent predicted, rising 330 mL or 15 percent); type 2 inflammation (FeNO 38 ppb, blood eosinophils 0.38 x10^3/uL, total IgE 165, house dust mite sensitization); tuberculosis infection test negative and chest X-ray clear. Triggers: cold air, kitchen and fireplace smoke, colds | active | confirmed | J45.30 | S — Synthetic modern confirmation linked to her documented frail, asthmatic childhood and her own later descriptions of asthma. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Spirometry with bronchodilator response, read with race-neutral equations | At diagnosis, before starting controller therapy | Completed today | FEV1 2.24 L (83 percent) to 2.57 L (+330 mL, +15 percent); FEV1/FVC 0.72 to 0.80 |
| Imaging | FeNO | When the diagnosis is uncertain, and to monitor response (NAEPP, conditional) | Completed today | 38 ppb, intermediate |
| Laboratory | Blood eosinophils and total and specific IgE (phenotyping) | At diagnosis | Completed today | Eosinophils 0.38 two weeks ago; total IgE 165; house dust mite specific IgE positive; cat and mold negative |
| Laboratory | Exclusion of tuberculosis and other chest disease | At diagnosis, for a person born where tuberculosis is common | Up to date | Interferon-gamma release assay negative and chest X-ray clear at the first visit |
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 16; symptoms three or four days a week; night waking twice a month |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Taught today with her new inhaler and a spacer; demonstrated correctly |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Written plan with peak flow zones given |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | No oral corticosteroid course, emergency visit or admission ever |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | Starting at step 2: as-needed low-dose budesonide-formoterol |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Never smoked or vaped; cold air, cooking and fireplace smoke, colds; house dust mite sensitization |
| Examination | Comorbidities: rhinitis, reflux, mood, anxiety | At diagnosis and yearly | Completed today | No rhinitis or reflux symptoms; PHQ-2 1 at the first visit |
| Self-management | Vaccinations | Yearly | Completed today | Influenza, COVID-19 and PCV20 today |
| Referral | Biologic assessment | When asthma is severe or uncontrolled despite optimized step 4 to 5 treatment | Not indicated | Mild asthma; treatment has only now started |
| Self-management | Equity: race-neutral interpretation and plain explanation | Every test | Completed today | Read with GLI Global equations; results explained to her in plain words, with a printed copy for her |
| Self-management | Private conversation: consent, safety and exploitation, and her own decisions | Every visit | Completed today | Seen alone; she consented to each test and treatment; results kept to her own contact details |
Goal progress:
Immunizations given today: Influenza vaccine, this season; COVID-19 mRNA vaccine, this season's formula; Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Six-week review. Follow the action plan: more reliever inhalations and a call to the clinic in the yellow zone; emergency care in the red zone. Next scheduled visit 2026-04-06: six-week asthma review: control, technique, personal best peak flow, triggers, and planning for a long sea journey and a summer away. [S]